Chiron Off The Hook For Securities Violations

Law360, New York (February 7, 2006, 12:00 AM EST) -- The U.S. Securities and Exchange Commission has closed its investigation into whether Chiron Corp. violated any federal securities laws, the biotech company said Tuesday.

In October 2004, the SEC began informally investigating Chiron in connection with the unexpected suspension of Chiron's license to manufacture an influenza virus vaccine, Fluviron, by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency. The suspension was due to concerns of contamination.

U.S. securities regulators wanted to know what the company could and should have told investors about its vaccine manufacturing...
To view the full article, register now.